What should South African HIV vaccine trials do about social harms?

AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV

Volumn 19, Issue 9, 2007, Pages 1110-1117

  Milford, C ^a,b   Barsdorf, N ^a   Kafaar, Z ^c  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^c STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL; DOMESTIC VIOLENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL LITERATURE; PRIORITY JOURNAL; RISK FACTOR; SOCIAL ASPECT; SOUTH AFRICA; THAILAND;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS VACCINES; ATTITUDE TO HEALTH; CLINICAL TRIALS AS TOPIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; HARM REDUCTION; HIV SEROPOSITIVITY; HUMANS; SOUTH AFRICA;

EID: 36849073635     PISSN: 09540121     EISSN: 13600451     Source Type: Journal    
DOI: 10.1080/09540120701335212     Document Type: Article

References (45)

1. Allen, M. (2001). Trial-related discrimination in HIV vaccine clinical trials. AIDS Research and Human Retroviruses, 17, 667-668.
2. Baleta, A. (1999). South Africa faces an AIDS crisis as government health campaigns fail. Lancet, 353, 653.
3. Bartholow, B.N., Buchbinder, S., Goli, V., Celum, C., Koblin, B., Marmor, M., et al. (2002). HIV risk behaviour change over 24 months of follow-up in a Phase-III HIV vaccine efficacy trial. Abstract of paper presented at XIV International AIDS Conference, Barcelona, August.
4. Bartholow, B., Buchbinder, S., Celum, C., Goli, V., Koblin, B., Para, M., et al. (2005). HIV sexual risk behaviour over 36 months of follow-up in the world's first HIV vaccine efficacy trial. Journal of Acquired Immune Deficiency Syndromes, 39, 90-101.
5. Belshe, R.B., Stevens, C., Gorse, G.J., Buchbinder, S., Weinhold, K., Sheppard, H., et al. (2001). Safety and immunogenicity of a canarypox-vectored HIV type 1 vaccine with or without GP 120. Journal of Infectious Diseases, 183, 1343-1352.
6. Buchbinder, S., Metch, B., Holte, S.E., Scheer, S., Coletti, A., & Vittinghoff, E. (2004). Determinants of enrollment in a preventive HIV vaccine trial: Hypothetical versus actual willingness and barriers to participation. Journal of Acquired Immune Deficiency Syndromes, 36, 604-612.
7. Buchbinder, S., Wheeler, S., Vittinghoff, E., McKirnan, D., Celum, C., Mayer, K., et al. (2003). Declines in risk behaviour are smaller in Phase III vaccine trial participants than in a nonvaccine trial control group. Abstract of paper presented at AIDS Vaccine Conference, New York, September.
8. Chesney, M.A., Chambers, D.B., & Kahn, J.O. (1997). Risk behavior for HIV infection in participants in preventive HIV vaccine trials: A cautionary note. Journal of Acquired Immune Deficiency Syndromes, 16, 266-271.
9. Coletti, A.S., Heagerty, P., Sheon, A.R., Gross, M., Koblin, B.A., Metzger, D.S., et al. (2003). Randomised, controlled evaluation of a prototype informed consent process for HIV vaccine efficacy trials. Journal of Acquired Immune Deficiency Syndromes, 32, 161-169.
10. Dawes, A., Kafaar, Z., de Sas Kropiwnicki, Z.O., Pather, R., & Richter, L. (2004). Partner violence, attitudes to child discipline and the use of corporal punishment: A South African national survey. Cape Town, South Africa: Child Youth & Family Development, Human Sciences Research Council.
11. Deacon, H., Stephney, I., & Prosalendis, S. (2005). Understanding HIV/AIDS stigma: A theoretical and methodological analysis (p. 23). Cape Town, South Africa: HSRC Press.
12. Dunkle, K.L., Jewkes, R.K., Brown, H.C., Gray, G.E., McIntyre, J.A., & Harlow, S.D. (2004). Gender-based violence, relationship power, and risk of HIV infection among women attending antenatal clinics in South Africa. Lancet, 363, 1415-1421.
13. Fuchs, J., Durham, M., McLellan-Lemal, E., Vittinghoff, E., Buchbinder, S., & Vax Study Team (2004). Younger HIV vaccine trial participants report negative social impacts [ThPeC7444]. Abstract of paper presented at XV International AIDS Conference, Bangkok, July.
14. Goffman, E. (1963). Stigma: Notes on the management of a spoiled identity. New York: Simon & Schuster.
15. Grady, C. (1994). HIV-preventive vaccine research: Selected ethical issues. Journal of Medicine and Philosophy, 19, 595-612.
16. Gupta, G.R. (2005). Luncheon remarks on women and AIDS. Paper presented at Interactive Forum, Loews L'Enfant Plaza Hotel, June, Washington DC.
17. Harrison, A., Smit, J.A., & Myer, L. (2000). Prevention of HIV/ AIDS in South Africa: A review of behaviour change interventions, evidence and options for the future. South African Journal of Science, 96, 285-290.
18. Herek, G.M. (2002). Thinking about AIDS and stigma: A psychologist's perspective. Journal of Law, Medicine and Ethics, 30, 594-607.
19. Herek, G.M., & Capitanio, J.P. (1998). Symbolic prejudice or fear of infection? A functional analysis of AIDS-related stigma. Basic and Applied Social Psychology, 20, 230-241.
20. Jenkins, R.A., Thapinta, D., Morgan, P.A., Wongkamhaeng, S., Sornsathapornkul, P., Bussaratid, V., et al., & Thai AIDS Vaccine Evaluation Group (2005). Behavioural and social issues among volunteers in a preventive HIV vaccine trial in Thailand. Journal of Acquired Immune Deficiency Syndromes, 40, 592-599.
21. Jenkins, R., Torugsa, K., Markowitz, L., Mason, C., Jamroentana, V., Brown, A., et al. (2000). Willingness to participate in HIV-1 vaccine trials among Thai men. Sexually Transmitted Infections, 76, 386-392.
22. Jermano, J. (2000). Monitoring of social and behavioral harms in the Phase III trial of AIDS VAX(r) B/B [ThOrD679]. Abstract of paper presented at XIII International AIDS Conference, Durban, August.
23. Jewkes, R., Levin, J., & Penn-Kekana, L. (2002). Risk factors for domestic violence: Findings from a South African cross-sectional study. Social Science and Medicine, 55, 1603-1617.
24. Leider, P.A. (2000). Domestic AIDS vaccine trials: Addressing the potential for social harm to the subjects of human experiments. California Law Review, 88, 1185-1232.
25. Link, B.G., & Phelan, J.C. (2001). Conceptualising stigma. Annual Review of Sociology, 27, 363-385.
26. MacQueen, K.M., Buchbinder, S., Douglas, J.M., Judson, F.N., McKirnan, D.J., & Bartholow, B. (1996). Required HIV antibody testing, social risk, and HIV-vaccine efficacy trials. AIDS Public Policy Journal, 11, 104-112.
27. Maduna-Butshe, A.C.Z. (1997). Women sex workers and the pandemic: Stigma and blame in context. South African AIDS News, 5, 8-11.
28. Maek-A-Nantawat, W., Pitisuttithum, P., Phonrat, B., Bussaratid, V., Naksrisook, S., Peonim, W., et al. (2003). Evaluation of attitude, risk behaviour and expectations among Thai participants in Phase I/II HIV/AIDS vaccine trials. Journal of the Medical Association of Thailand, 86, 299-307.
29. Melkote, S.R., Muppidi, S.R., & Goswami, D. (2000). Social and economic factors in an integrated behavioural and societal approach to communications in HIV/AIDS. Journal of Health Communication, 5(Suppl.), S17-S27.
30. Muyinda, H., Seeley, J., Pickering, H., & Barton, J. (1997). Social aspects of AIDS-related stigma in rural Uganda. Health Place, 3, 143-147.
31. Parker, R., & Aggleton, P. (2003). HIV and AIDS-related stigma and discrimination: A conceptual framework and implications for action. Social Science and Medicine, 57, 13-24.
32. Pitisuttithum, P. (2000). Social harm monitoring among injecting drug users in a Phase III HIV vaccine trial in Bangkok, Thailand: Preliminary results [TuOrD448]. Abstract of paper presented at XIII International AIDS Conference, Durban, August.
33. Pitisuttithum, P., Martin, M., & Vanichseni, S. (2004). Social impact and harm among injecting drug users (IDUs) in a Phase II HIV vaccine trial in Thailand [C11162]. Abstract of paper presented at XV International AIDS Conference, Bangkok, July.
34. Sheon, A., Wagner, L., McElrath, M., Keefer, M., Zimmerman, E., Israel, H., et al. (1998). Preventing discrimination against volunteers in prophylactic HIV vaccine trials: Lessons from a Phase II trial. Journal of Acquired Immune Deficiency Syndromes, 19, 519-526.
35. South African AIDS Vaccine Initiative (2002). Long-term insurance industry HIV testing protocol - changes to accommodate HIV vaccine trials. Available at: http://www.saavi.org.za/press26sep2002.htm
36. South African Medical Research Council (2001). Guidelines on ethics for medical research: General principles. Tygerberg, South Africa: Author.
37. South African Medical Research Council (2003). Guidelines on ethics for medical research: HIV-preventive vaccine research. Tygerberg, South Africa: Author.
38. Temoshok, L.R. (1994). Behavioral research contributions to planning and conducting HIV vaccine efficacy studies. AIDS Research and Human Retroviruses, 10, S277-S280.
39. Thapinta, D., Jenkins, R.A., Celentano, D.D., Nitayaphan, S., Buapunth, P., Triampon, A., et al. (1999). Evaluation of behavioral and social issues among Thai HIV vaccine trial volunteers. Journal of Acquired Immune Deficiency Syndromes, 20, 308-315.
40. UNAIDS (2000). Ethical Considerations in HIV-preventive Vaccine Research: UNAIDS Guidance Document. Geneva, Switzerland: UNAIDS.
41. UNAIDS (2006). Report on the Global AIDS Epidemic. Geneva, Switzerland: UNAIDS.
42. van Griensven, F., Vanichseni, S., Tappero, J., Pitisuttithum, P., Kitayaporn, D., Martin, M., et al. (2003). Monitoring of risk behaviour among injection drug users (IDU) in the AIDSVAX B/E vaccine trial in Bangkok: 36 months of follow-up. Abstract of paper presented at AIDS Vaccine Conference, New York, September.
43. Wassenaar, D., & Barsdorf, N. (2007). The involvement of women in HIV vaccine trials in Africa. Women and Health, 45, (in press).
44. Wassenaar, D. (2005). WHO-UNAIDS Expert Group (2005). Gender, age and ethnicity in HIV vaccine-related research and clinical trials: Report from a WHO-UNAIDS consultation, 26-28 August 2004, Lausanne, Switzerland. AIDS, 19, 7-28.
45. WHO-UNAIDS Expert Group. (2005). Gender, age and ethnicity in HIV vaccine-related research and clinical trials: report from a WHO-UNAIDS consultation, 26-28 August 2004. Lausanne, Switzerland. AIDS, 19, W7-W28.